Evaluation of large-scale combination HIV prevention programs: Essential issues

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 2, 2011, Pages

  Padian, Nancy S ^a,b,c   McCoy, Sandra I ^b   Manian, Shanthi ^b   Wilson, David ^d   Schwartländer, Bernhard ^e   Bertozzi, Stefano M ^c,e,f,g  

^a U S DEPARTMENT OF STATE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

^d WORLD BANK   (United States)

^e UNAIDS   (Switzerland)

^f UNIVERSITY OF WASHINGTON   (United States)

^g INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

HIV; impact evaluation; implementation science; monitoring and evaluation; operations research

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE MARKER; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MORBIDITY; MORTALITY; PATIENT EDUCATION; PREVALENCE; PRIORITY JOURNAL;

CONTROL GROUPS; HIV INFECTIONS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PROGRAM EVALUATION; SAMPLE SIZE;

EID: 80052964105     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318227af37     Document Type: Article

References (46)

1. Padian NS, McCoy SI, Balkus JE, et al. Weighing the Gold in the Gold Standard: Challenges in HIV Prevention Research. AIDS. 2010;24:621-635.
2. Padian NS, Buve A, Balkus J, et al. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 2008;372: 585-599.
3. Piot P, Bartos M, Larson H, et al. Coming to terms with complexity: a call to action for HIV prevention. Lancet. 2008;372:845-859.
4. Merson M, Padian N, Coates TJ, et al. Combination HIV prevention. Lancet. 2008;372:1805-1806.
5. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
6. National Institutes of Health. Daily Dose of HIV Drug Reduces Risk of HIV Infection. NIH's NIAID-sponsored study finds pre-exposure prophylaxis concept effective among men who have sex with men. Press Release 2010; Available at: http://www.niaid.nih.gov/news/newsreleases/2010/Pages/iPrEx.aspx. Accessed November 30, 2010.
7. Network of Networks for Impact Evaluation (NONIE). Impact Evaluations and Development. Washington, DC; NONIE; 2009.
8. Victora CG, Black RE, Boerma JT, et al. Measuring impact in the Millennium Development Goal era and beyond: a new approach to largescale effectiveness evaluations. Lancet. 2011;377:85-95.
9. Baker JL. Evaluating the Impact of Development Projects on Poverty: A Handbook for Practitioners. Washington, DC: The World Bank; 2000.
10. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008; 337:a1655.
11. Minnis AM, Steiner MJ, Gallo MF, et al. Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. Am J Epidemiol. 2009;170:918-924.
12. Peterman TA, Lin LS, Newman DR, et al. Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Project RESPECT Study Group. Sex Transm Dis. 2000;27:446-451. (Pubitemid 30666946)
13. Lagarde E, Auvert B, Chege J, et al. Condom use and its association with HIV/sexually transmitted diseases in four urban communities of sub-Saharan Africa. AIDS. 2001;15(suppl 4):S71-S78. (Pubitemid 32913006)
14. The Lancet. Evaluation: the top priority for global health. Lancet. 2010; 375:526.
15. KurthAE,CelumC,BaetenJM,etal.CombinationHIVprevention:significance, challenges, and opportunities. Curr HIV/AIDS Rep. 2011;8:62-72.
16. Duflo E, Kremer M. Use of randomization in the evaluation of development effectiveness. Conference on Evaluation and Development Effectiveness; July 15-16, 2003; Washington, DC.
17. Parker SW, Teruel GM. Randomization and Social Program Evaluation: The Case of Progresa. Ann Am Acad Polit Soc Sci. 2005;599:199-219. (Pubitemid 40580096)
18. Rivera JA, Sotres-Alvarez D, Habicht JP, et al. Impact of the Mexican program for education, health, and nutrition (Progresa) on rates of growth and anemia in infants and young children: a randomized effectiveness study. JAMA. 2004;291:2563-2570. (Pubitemid 38702774)
19. Hall AJ, Inskip HM, Loik F, et al. The Gambia Hepatitis Intervention Study. Cancer Res. 1987;47:5782-5787. (Pubitemid 18046781)
20. Viviani S, Carrieri P, Bah E, et al. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:3216-3223.
21. Victora CG, Habicht JP, Bryce J. Evidence-based public health: moving beyond randomized trials. Am J Public Health. 2004;94:400-405. (Pubitemid 38269492)
22. Habicht JP, Victora CG, Vaughan JP. Evaluation designs for adequacy, plausibility and probability of public health programme performance and impact. Int J Epidemiol. 1999;28:10-18. (Pubitemid 29086204)
23. Peterman TA. Can we measure STD risk behavior or STD as surrogates for HIV risk? Presented at International Congress of Sexually Transmitted Infections (ISSTDR/IUSTI); 2001; Bundesgesundheitsblatt-Gesundheitsforschung- Gesundheitsschutz: Berlin, Germany.
24. Office of US Global AIDS Coordinator. Operational plans of the US president's emergency plan for AIDS relief (PEPFAR). 2010; Available at: http://2006-2009.pepfar.gov/about/c19388.htm. Accessed November 17, 2010.
25. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol. 2006;6:54.
26. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials. 2007;28:182-191. (Pubitemid 44937879)
27. Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington, DC: Institute of Medicine; 2010.
28. Aral SO, Peterman TA. A stratified approach to untangling the behavioral/biomedical outcomes conundrum. Sex Transm Dis. 2002;29:530-532. (Pubitemid 35001342)
29. Gray RH, Wawer MJ. Reassessing the hypothesis on STI control for HIV prevention. Lancet. 2008;371:2064-2065. (Pubitemid 351842568)
30. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
31. Stephenson J, Imrie J. Why do we need randomised controlled trials to assess behavioural interventions? BMJ. 1998;316:611-613. (Pubitemid 28120999)
32. Rosen L, Manor O, Engelhard D, et al. In defense of the randomized controlled trial for health promotion research. Am J Public Health. 2006; 96:1181-1186. (Pubitemid 43967841)
33. Bonell C, Hargreaves J, Strange V, et al. Should structural interventions be evaluated using RCTs? The case of HIV prevention. Soc Sci Med. 2006; 63:1135-1142. (Pubitemid 44037137)
34. Arifeen SE, Hoque DM, Akter T, et al. Effect of the integrated management of childhood illness strategy on childhood mortality and nutrition in a rural area in Bangladesh: a cluster randomised trial. Lancet. 2009;374:393-403.
35. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346:530-536.
36. Pronyk PM, Hargreaves JR, Kim JC, et al. Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial. Lancet. 2006;368: 1973-1983. (Pubitemid 44821362)
37. The Gambia Hepatitis Intervention Study. The Gambia Hepatitis Study Group.Cancer Res. 1987;47:5782-5787.
38. Arifeen SE, Hoque E, Akter T, et al. Effect of the integrated management of childhood illness strategy on childhood mortality and nutrition in a rural area in Bangladesh: a cluster randomised trial. Lancet. 2009;374: 393-403.
39. Skoufias E. PROGRESA and Its Impacts on the Welfare of Rural Households in Mexico. Washington, DC: International Food Policy Research Institute; 2005.
40. The World Bank. CCT programs: now on every continent. Available at: http://go.worldbank.org/2NS1R2QIM0. Accessed January 17, 2011.
41. Arnold BF, Khush RS, Ramaswamy P, et al. Causal inference methods to study nonrandomized, preexisting development interventions. Proc Natl Acad Sci USA. 2010;107:22605-22610.
42. Hallett TB, Zaba B, Todd J, et al. Estimating incidence from prevalence in generalised HIVepidemics: methods and validation. PLoS Med. 2008; 5:e80.
43. Rehle TM, Hallett TB, Shisana O, et al. A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One. 2010;5: e11094.
44. Chow S, Chang M. Adaptive Design Methods in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC; 2006.
45. Bauer P, Brannath W. The advantages and disadvantages of adaptive designs for clinical trials. Drug Discov Today. 2004;9:351-357. (Pubitemid 38479690)
46. van der Laan MJ. The Construction and Analysis of Adaptive Group Sequential Designs. Berkeley, CA: U.C. Berkeley Division of Biostatistics Working Paper Series, University of California; 2008.